124 related articles for article (PubMed ID: 7615375)
1. How significant are serial bone scans in monitoring advanced prostatic cancer?
Tekgül S; Ozen H; Ozyavuz R; Bakkaloğlu M; Remzi D
Int Urol Nephrol; 1995; 27(1):87-91. PubMed ID: 7615375
[TBL] [Abstract][Full Text] [Related]
2. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
3. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
Pollen JJ; Witztum KF; Ashburn WL
AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
[TBL] [Abstract][Full Text] [Related]
4. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
[TBL] [Abstract][Full Text] [Related]
5. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
6. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
7. Extensive bone metastases in a patient with prostatic adenocarcinoma and normal serum prostate-specific antigen and prostatic acid phosphatase.
Yuksel M; Cermik TF; Kaya M; Salan A; Ustun F; Salihoglu YS; Yigitbasi ON; Berkarda S
Clin Nucl Med; 2001 Nov; 26(11):962. PubMed ID: 11595863
[No Abstract] [Full Text] [Related]
8. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy.
Terris MK; Klonecke AS; McDougall IR; Stamey TA
J Nucl Med; 1991 Sep; 32(9):1713-7. PubMed ID: 1715394
[TBL] [Abstract][Full Text] [Related]
11. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
12. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
13. Super bone scan: bone metastases of prostate cancer.
Shikino K; Ikusaka M; Hirota Y; Sato E
BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25228679
[No Abstract] [Full Text] [Related]
14. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging for detection of prostate cancer metastatic to bone.
Turner JW; Hawes DR; Williams RD
J Urol; 1993 Jun; 149(6):1482-4. PubMed ID: 8501793
[TBL] [Abstract][Full Text] [Related]
16. The role of routine followup bone scans after definitive therapy of localized prostatic cancer.
Huben RP; Schellhammer PF
J Urol; 1982 Sep; 128(3):510-2. PubMed ID: 6214643
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Yahara J; Noguchi M; Noda S
BJU Int; 2003 Sep; 92(4):379-83; discussion 383-4. PubMed ID: 12930424
[TBL] [Abstract][Full Text] [Related]
18. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
19. Case report: accumulation of 99mTc-hydroxymethylene diphosphonate by liver metastases of prostatic adenocarcinoma.
Mannion RA; Johnson M
Clin Radiol; 1993 Mar; 47(3):209-10. PubMed ID: 8472488
[TBL] [Abstract][Full Text] [Related]
20. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
